ProShare Advisors LLC Sells 574 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

ProShare Advisors LLC cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,865 shares of the specialty pharmaceutical company’s stock after selling 574 shares during the quarter. ProShare Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $733,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its position in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the period. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares in the last quarter. Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $33,000. Finally, Assetmark Inc. raised its stake in shares of Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 119 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ JAZZ opened at $110.93 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.38. The firm’s 50-day simple moving average is $111.02 and its 200 day simple moving average is $110.82. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company has a market cap of $7.00 billion, a price-to-earnings ratio of 22.87, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. On average, research analysts expect that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. UBS Group decreased their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.